Al-Zubaidi Mohammed, Lotter Kennia, Marshall Martin, Lozinskiy Mikhail
Department of Urology, Royal Perth Hospital, Perth, Australia.
Department of Radiology, Royal Perth Hospital, Perth, Australia.
Asian J Urol. 2023 Apr;10(2):177-181. doi: 10.1016/j.ajur.2021.10.003. Epub 2021 Nov 6.
This study aimed to evaluate the safety and efficacy outcomes of percutaneous radiofrequency ablation (RFA) for localised renal cell carcinoma (RCC) in a tertiary hospital patient who remained unfit for surgical intervention.
We retrospectively analysed survival outcomes for patients with biopsy proven RCC treated by RFA at Royal Perth Hospital between September 2009 and May 2018. Complication data were gathered for all patients that underwent renal RFA along with 2- and 5-year recurrence-free survival (RFS) rate and compared the outcomes with data from previous studies.
A total of 69 patients (73 procedures) were eligible for the study, and those patients had biopsy-proven RCC with a minimum of 2-year follow-up. The complication rate was 8.2% (6/73) and local recurrence rate 9.6% (7/73). Two-year RFS is 95.7% and 5-year RFS is 78.8% on a median 3.82-year follow-up (interquartile range 1.90-5.75 years).
RFA performed at our centre was found to be safe and effective with low complication rates and durable RFS in line with expectations from existing research. Our study demonstrated that RFA is an alternative modality of treatment for small renal tumours in patients unfit for surgical approach.
本研究旨在评估在一家三级医院中，经皮射频消融术（RFA）对不适于手术干预的局限性肾细胞癌（RCC）患者的安全性和疗效结果。
我们回顾性分析了2009年9月至2018年5月在皇家珀斯医院接受RFA治疗且活检证实为RCC患者的生存结果。收集了所有接受肾脏RFA患者的并发症数据以及2年和5年无复发生存率（RFS），并将结果与先前研究的数据进行比较。
共有69例患者（73例手术）符合研究条件，这些患者经活检证实为RCC，且至少随访2年。并发症发生率为8.2%（6/73），局部复发率为9.6%（7/73）。在中位3.82年的随访期（四分位间距1.90 - 5.75年）内，2年RFS为95.7%，5年RFS为78.8%。
我们中心进行的RFA被发现是安全有效的，并发症发生率低，RFS持久，与现有研究的预期一致。我们的研究表明，RFA是不适于手术治疗的小肾肿瘤患者的一种替代治疗方式。
